Print Page     Close Window     

SEC Filings / Section 16 Reports

DEF 14A
BECTON DICKINSON & CO filed this Form DEF 14A on 12/03/2018
Entire Document
 

 
Appendix A
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

Presented below are reconciliations of non-GAAP financial measures discussed in the Compensation Discussion and Analysis section of this proxy statement to the comparable GAAP financial measure. All figures below are rounded, and totals may not add due to rounding.

2018 Comparable Currency-Neutral Revenue Growth
2018 Comparable Revenues
 
 
A
 
B
 
C
 
D
 
E=A+B+C+D
 
 
BD Reported
 
Bard Q1 (b)
 
Intercompany Adjustment (c)
 
Divestiture Adjustments (d)
 
Comparable
2018
 
Total Revenues
 
$15,983
 
$968
 
$(3)
 
$(18)
 
$16,930

2017 Comparable Revenues
 
 
A
 
B
 
C
 
D
 
E=A+B+C+D
 
 
BD Reported
 
Bard (b)
 
Intercompany Adjustment (c)
 
Divestiture Adjustments (d)
 
Comparable
2017
 
Total Revenues
 
$12,093
 
$3,702
 
$(14)
 
$(48)
 
$15,732
Comparable Growth
 
A
 
B
 
C
 
D=(A-B-C)/B
 
2018 Comparable Revenues
 
2017 Comparable Revenues
 
Foreign Exchange Impact
 
Currency-Neutral Growth
 
 
$16,930
 
$15,732
 
$279
 
5.8%
______________________
(a)
Amounts in 2018 represent revenues for the quarter ended December 31, 2017; amounts in 2017 represent revenues for the quarterly periods included in BD's fiscal year 2017. Amounts presented in alignment with BD's current-period segment, organizational unit and regional reporting structure. Also reflects the elimination of revenues from the Peripheral Intervention unit related to a royalty income stream, reported as revenues by Bard, which BD reports as non-operating income in the current-year period.
(b)
Represents the elimination of revenues from the Medication Delivery Solutions unit which BD previously recognized from Bard as third-party revenues and that would be treated as intercompany revenues in the current-year period.
(c)
Represents adjustments for BD's divestiture of its soft tissue core needle biopsy product line and Bard's divestiture of its Aspira® product line.


A-1